Magnet Biomedicine utilizes its TrueGlue™ discovery platform to systematically design monovalent molecular glues that target specific protein pairs for therapeutic applications. This approach addresses the challenge of treating complex diseases, such as cancer and autoimmune disorders, by enabling tissue-specific drug effects while minimizing off-target toxicity.
Funding
$50.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NMFounders
Product
Problem
Many diseases, including cancers and autoimmune disorders, require precise therapeutic interventions that minimize off-target toxicity and maximize efficacy in specific tissues. Traditional small molecule drugs often lack the required specificity, leading to systemic side effects and limited therapeutic windows.
Solution
Magnet Biomedicine is developing a new class of therapeutics based on rationally designed monovalent molecular glues. Their TrueGlue™ discovery platform systematically identifies and engineers molecular glues that selectively bind to specific protein pairs, inducing proximity and modulating protein function in a tissue-localized manner. By targeting disease-relevant tissues, TrueGlues offer the potential to enhance therapeutic efficacy while minimizing off-target effects. This approach enables the development of novel medicines for challenging targets and indications, including cancer, immune disorders, and cardiovascular disease.
Target Audience
The primary target audience includes patients with cancer, autoimmune disorders, and cardiovascular diseases, as well as pharmaceutical companies seeking novel therapeutic modalities for challenging targets.
Features
- TrueGlue™ discovery platform for systematic design of monovalent molecular glues
- Rational selection of protein pairs to maximize therapeutic impact
- Tissue-specific drug effects to minimize off-target toxicity
- Ability to induce biological synergy and target historically undruggable proteins
- Modulation of protein localization to enable novel mechanisms of action
- State-of-the-art screening technologies utilizing diverse chemical libraries
- Human biology–driven target and presenter selection
- Integration of in-house and external data to discover and exploit novel molecular glue mechanisms of action